PAR-101

BACKGROUND Due to the limitations of existing treatment options for Clostridium difficile infection (CDI), new therapies are… Expand

OBJECTIVE To review the chemistry, pharmacology, microbiology, pharmacodynamics, pharmacokinetics, clinical efficacy… Expand

The two drugs currently recommended for the treatment of Clostridium difficile infection (CDI), namely vancomycin and… Expand

Objective: To evaluate the pharmacology, microbiology, safety, and efficacy of fidaxomicin for treatment of Clostridium difficile… Expand

The effects of the inoculum, pH, cation concentrations, and different lots of commercial media on the in vitro susceptibility of… Expand

Fidaxomicin, an RNA polymerase inhibitor, is being developed by Optimer and Par Pharmaceuticals as a narrow-spectrum… Expand

Objective: To evaluate the efficacy and safety of fidaxomicin for the treatment of Clostridium difficile infection. Data Sources… Expand

BACKGROUND Clostridium difficile-associated diarrhoea has become a major problem over the last years. Increasing incidence and… Expand

Background: Clostridium difficile-associated diarrhoea has become a major problem over the last years. Increasing incidence and… Expand

Clostridium difficile-associated disease (CDAD) has become an important public health problem. The causative organism is acquired… Expand